



Condensed Financial Statement And Dividend Announcement For The First Half Ended 30 June 2025 (“1H25”)

1(a) Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Note	Group		
		Year-To-Date		
		30/06/2025 \$'000	30/06/2024 \$'000 (Restated) ¹	Change %
Revenue				
Core Dental Business		87,203	84,232	4
Other Businesses		1,175	4,560	(74)
Total Revenue	3	88,378	88,792	-
Other Items of Income				
Interest Income		24	38	(37)
Other Items of Expense				
Cost of Sales – Core Dental Business		(9,695)	(8,350)	16
Cost of Sales – Other businesses		(210)	(1,285)	(84)
Employee Benefits Expense		(51,649)	(52,190)	(1)
Depreciation and Amortisation Expense		(2,512)	(2,517)	-
Depreciation of Right-Of-Use Assets		(6,490)	(6,528)	(1)
Other Expenses		(6,163)	(5,526)	12
Finance Costs	5	(2,340)	(2,700)	(13)
Other (Losses) Gains - Net	4	(4,404)	1,763	NM
Share of (Loss) Profit from Equity-Accounted Associates		(103)	68	NM
Profit Before Tax from Continuing Operations		4,836	11,565	(58)
Income Tax Expense	6	(832)	(1,530)	(46)
Profit from Continuing Operations, Net of Tax		4,004	10,035	(60)
Other Comprehensive (Loss) Income:				
Exchange Differences on Translating Foreign Operations, Net of Tax		(1,138)	1	NM
Other Comprehensive (Loss) Income for the Period, Net of Tax		(1,138)	1	NM
Total Comprehensive Income for the Period		2,866	10,036	(71)
Profit Attributable to:				
Owners of the Parent, Net of Tax		3,856	9,651	(60)
Non-Controlling Interests, Net of Tax		148	384	(61)
Profit, Net of Tax		4,004	10,035	(60)
Profit Excluding Other Gains (Losses) Attributable to:				
Owners of the Parent, Net of Tax		8,291	7,874	5
Non-Controlling Interests, Net of Tax		117	398	(71)
Profit, Net of Tax		8,408	8,272	2
Profit From Core Dental Business, Net of Tax	2B	13,679	12,459	10
Total Comprehensive Income Attributable to:				
Owners of the Parent		2,805	9,652	(71)
Non-Controlling Interests		61	384	(84)
Total Comprehensive Income		2,866	10,036	(71)

NM: Not Meaningful

¹Refer to note 17



	Note	Group		
		Year-To-Date		
		30/06/2025 \$'000	30/06/2024 \$'000 (Restated) ¹	Change %
EBITDA		16,154	23,272	(31)
Earnings Per Share				
Base on the Weighted Average Number of Ordinary ^(a)				
Shares on Issue – Cents		0.41	1.02	
Fully Diluted Basis – Cents		0.41	1.02	
Excluding Other Gains (Losses):				
EBITDA		20,558	21,509	(4)
Earnings Per Share				
Base on the Weighted Average Number of Ordinary ^(a)				
Shares on Issue – Cents		0.87	0.83	
Fully Diluted Basis – Cents		0.87	0.83	

¹Refer to note 17

- (a) The basic EPS for the period ended 30 June 2025 and 30 June 2024 are based on the profit attributable to equity holders of parent, net of tax and weighted average number of ordinary shares of 948,738,987 and 946,452,913 shares respectively.



1(b) Condensed Interim Statements of Financial Position

	Note	Group		Company	
		As at		As at	
		30/06/2025	31/12/2024	30/06/2025	31/12/2024
		\$'000	\$'000 (Restated) ¹	\$'000	\$'000
ASSETS					
Non-Current Assets					
Property, Plant and Equipment	8	40,885	37,056	1,001	1,092
Right-Of-Use Assets		40,295	38,182	1,261	1,389
Investment in Subsidiaries		-	-	102,125	59,980
Investment in Associates	9	15	25,835	-	33,832
Goodwill	10	77,004	52,357	-	-
Other Intangible Assets	11	4,214	427	-	-
Other Receivables		2,583	2,933	1,816	2,032
Other Assets		5,751	6,549	2,591	2,864
Total Non-Current Assets		170,747	163,339	108,794	101,189
Current Assets					
Inventories		12,392	10,587	-	-
Trade and Other Receivables		38,946	35,981	77,794	86,034
Other Assets		3,632	3,151	1,346	1,321
Cash and Cash Equivalents		47,051	34,342	8,759	3,867
Total Current Assets		102,021	84,061	87,899	91,222
Total Assets		272,768	247,400	196,693	192,411
EQUITY AND LIABILITIES					
Equity Attributable to Owners of the Parent					
Share Capital	12	86,758	86,758	86,758	86,758
Treasury Shares	12	(11,916)	(10,855)	(11,916)	(10,855)
Retained Earnings		30,757	33,301	14,991	17,981
Other Reserves, Total		(2,739)	(3,407)	-	-
Equity Attributable to Owners of the Parent, Total		102,860	105,797	89,833	93,884
Non-Controlling Interests		23,725	2,337	-	-
Total Equity		126,585	108,134	89,833	93,884
Non-Current Liabilities					
Provisions		997	985	-	-
Deferred Tax Liabilities		2,591	2,518	-	-
Lease Liabilities Arising from Right-Of-Use Assets		31,806	30,714	1,029	1,185
Other Financial Liabilities	13	73,022	73,239	67,060	67,167
Total Non-Current Liabilities		108,416	107,456	68,089	68,352
Current Liabilities					
Income Tax Payable		986	1,762	-	13
Trade and Other Payables		20,341	18,621	33,267	29,658
Lease Liabilities Arising from Right-Of-Use Assets		10,937	10,923	258	258
Other Financial Liabilities	13	5,503	504	5,246	246
Total Current Liabilities		37,767	31,810	38,771	30,175
Total Liabilities		146,183	139,266	106,860	98,527
Total Equity and Liabilities		272,768	247,400	196,693	192,411

¹Refer to note 17



1(c) Condensed Interim Consolidated Statement of Cash Flows

	Group	
	Year-To-Date	
	30/06/2025	30/06/2024
	\$'000	\$'000 (Restated) ¹
Cash Flows from Operating Activities		
Profit Before Tax	4,836	11,565
Adjustments for:		
Interest Income	(24)	(38)
Interest Expense	2,340	2,700
Plant and Equipment Written Off	160	103
Impairment allowance on plant and equipment	6	-
Gain on disposal of plant and equipment	(198)	-
Share of Loss (Profit) from Equity – Associated Associates	103	(68)
Loss on deemed disposal of associates	4,343	-
Gain on Disposal of Subsidiary	-	(436)
Depreciation of Property, Plant and Equipment and Amortisation Expense	2,512	2,517
Depreciation of Right-Of-Use Assets	6,490	6,528
Foreign Currency Translation Reserve	(291)	3
Operating Cash Flows Before Changes in Working Capital	20,277	22,874
Inventories	379	191
Trade and Other Receivables	1,287	(1,477)
Other non-financial assets	(248)	225
Trade and Other Payables	(4,991)	(2,416)
Net Cash Flows from Operating Activities Before Interest and Tax	16,704	19,397
Income Taxes Paid	(1,718)	(2,122)
Net Cash Flows from Operating Activities	14,986	17,275
Cash Flows From (Used in) Investing Activities		
Purchase of Property Plant and Equipment	(1,581)	(2,149)
Purchase of Intangible Assets	-	(152)
Disposal of Plant and Equipment	293	266
Other non-financial assets	888	1,199
Trade and Other Receivables	51	313
Disposal of Subsidiary (Net of cash)	-	(433)
Acquisition of Subsidiary (Net of cash)	9,874	-
Other Receivables, Non-Current	350	(187)
Interest Received	24	38
Net Cash Flows From (Used in) Investing Activities	9,899	(1,105)
Cash Flows Used in Financing Activities		
Lease Liabilities – Principal Portion Paid	(6,783)	(6,479)
Lease Liabilities – Interest Paid	(833)	(852)
Finance Lease Repayment	(7)	(4)
Repayment of Bank Loans	(220)	(3,183)
Proceeds from Term Loan	5,000	-
Proceeds from Placement Shares	-	130
Share buy back	(1,061)	-
Bill Payables	-	(620)
Interest Paid	(1,507)	(1,848)
Dividends Paid to Non-Controlling Interest	(123)	-
Dividends Paid to Equity Owners	(6,642)	(5,016)
Net Cash Flows Used in Financing Activities	(12,176)	(17,872)

¹Refer to note 17



Q & M Dental Group (Singapore) Limited
(Incorporated in the Republic of Singapore)
(Company Registration No: 200800507R)

	Group	
	Year-To-Date	
	30/06/2025	30/06/2024
	\$'000	\$'000 (Restated) ¹
Net increase (decrease) in Cash and Cash Equivalents	12,709	(1,702)
Cash and Cash Equivalents, Statement of Cash Flows, Beginning Balance of the Period	34,342	33,993
Cash and Cash Equivalents, Statement of Cash Flows, Ending Balance of the Period	47,051	32,291
Cash and Cash Equivalents at End of Period includes the following:		
Cash and Bank Balances	47,051	32,291
Cash and Cash Equivalents at End of Period	47,051	32,291

¹Refer to note 17



1(d)(i) Condensed Interim Statements of Changes in Equity

	<u>Total Equity</u>	<u>Attributable to Parent Sub-Total</u>	<u>Share Capital</u>	<u>Retained Earnings</u>	<u>Treasury Shares</u>	<u>Other Reserves</u>	<u>Non-Controlling Interest</u>
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
Group - Current Period							
Opening Balance at 1 January 2025	108,134	105,797	86,758	33,301	(10,855)	(3,407)	2,337
Movements in Equity:							
Total Comprehensive Income for the Period	2,866	2,805	-	3,856	-	(1,051)	61
Share Buy Back	(1,061)	(1,061)	-	-	(1,061)	-	-
Increase in Non-Controlling Interest with a Change in Control	21,692	242	-	242	-	-	21,450
Consolidation of Associate to a Subsidiary	1,719	1,719	-	-	-	1,719	-
Dividends Paid to Non-Controlling Interest	(123)	-	-	-	-	-	(123)
Dividends Paid (Note 7)	(6,642)	(6,642)	-	(6,642)	-	-	-
Closing Balance at 30 June 2025	126,585	102,860	86,758	30,757	(11,916)	(2,739)	23,725
Group - Previous Period							
Opening Balance at 1 January 2024	102,911	99,071	86,758	27,841	(11,535)	(3,993)	3,840
Movements in Equity:							
Total Comprehensive Income for the Period	10,036	9,652	-	9,651	-	1	384
Issuance of Ordinary Shares	130	130	-	-	130	-	-
Deconsolidation of Subsidiary	15	15	-	-	-	15	-
Dividends Paid (Note 7)	(5,016)	(5,016)	-	(5,016)	-	-	-
Closing Balance at 30 June 2024	108,076	103,852	86,758	32,476	(11,405)	(3,977)	4,224



1(d)(ii) Condensed Interim Statements of Changes in Equity

	<u>Total Equity</u>	<u>Share Capital</u>	<u>Treasury Shares</u>	<u>Other Reserve</u>	<u>Retained Earnings</u>
	\$'000	\$'000	\$'000	\$'000	\$'000
Company - Current Period					
Opening Balance at 1 January 2025	93,884	86,758	(10,855)	-	17,981
Movements in Equity:					
Total Comprehensive Income for the Period	3,652	-	-	-	3,652
Share Buy Back	(1,061)	-	(1,061)	-	-
Dividends Paid (Note 7)	(6,642)	-	-	-	(6,642)
Closing Balance at 30 June 2025	89,833	86,758	(11,916)	-	14,991
Company - Previous Period					
Opening Balance at 1 January 2024	86,271	86,758	(11,535)	-	11,048
Movements in Equity:					
Total Comprehensive Income for the Period	3,459	-	-	-	3,459
Issurance of Ordinary Shares	130	-	130	-	-
Dividends Paid (Note 7)	(5,016)	-	-	-	(5,016)
Closing Balance at 30 June 2024	84,844	86,758	(11,405)	-	9,491



1(e) Notes to the Condensed Interim Financial Statements
30 June 2025

1. General

The Company is incorporated in Singapore with limited liability. It is listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). The financial statements are presented in Singapore dollars and they cover the Company (referred to as “parent”) and the subsidiaries (collectively, the “Group”). The registered office is: 2 Clementi Loop, #04-01 Logis Hub @ Clementi, Singapore 129809. The Company is situated in Singapore.

The board of directors approved and authorised these condensed financial statements for issue on the date of this announcement. The directors have the power to amend and reissue the financial statements.

The principal activities of the Company are the provision of management and consultancy services and investment holding

The principal activities of the Group are disclosed in Note 2 on segment information.

The financial information contained in this announcement has neither been audited nor review by the Company auditors.

The latest audited annual financial statements were not subject to an adverse opinion, qualified opinion or disclaimer of opinion.

Basis of presentation

These condensed consolidated interim financial statements have been prepared in accordance with the Singapore Financial Reporting Standards (International) (“SFRS (I) s”) 1-34 Interim Financial Reporting issued by the Accounting Standards Committee Singapore. They are also in compliance with the International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board (IASB) and the provisions of the SGX Mainboard Listing Rules.

The accounting policies and methods of computation applied in these condensed consolidated interim financial statements are consistent with those of the latest audited annual financial statements for the reporting year ended 31 December 2024. However, the typical notes and information included in the latest audited annual financial statements are not included in these interim financial statements except for the selected explanatory notes included to explain events and transactions that are significant to an understanding of the changes in the performance and financial position of the group since the latest audited annual financial statements.

New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.



Critical judgements, assumptions and estimation uncertainties

These estimates and assumptions are periodically monitored to ensure they incorporate all relevant information available at the date when financial statements are prepared. However, this does not prevent actual figures differing from estimates. The nature and the carrying amount of such significant assets and liabilities are disclosed with further details in the relevant Notes to these condensed consolidated interim financial statements.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2024.

2. Financial information by operating segments

2A. Information about reportable segment profit or loss, assets and liabilities

The following summary describes the operations in each of the Group's operating segments:

- (i) Core dental business comprising dentistry and distribution of dental supplies and equipment.
- (ii) Other businesses comprising sale and distribution of Covid-19 test kits and provision of laboratory testing, family medicine, aesthetic services and others.



Q & M Dental Group (Singapore) Limited
(Incorporated in the Republic of Singapore)
(Company Registration No: 200800507R)

2B. Profit or loss for the 6 months ended 30 June from continuing operations and reconciliations

	<u>Core Dental Business</u>		<u>Other Businesses</u>		<u>Unallocated</u>		<u>Consolidated</u>	
	2025 \$'000	2024 \$'000	2025 \$'000	2024 \$'000	2025 \$'000	2024 \$'000 (Restated) ¹	2025 \$'000	2024 \$'000
Revenue by segment	87,405	84,425	1,611	4,703	-	-	89,016	89,128
Inter-segment sales	(202)	(193)	(436)	(143)	-	-	(638)	(336)
Total revenue	87,203	84,232	1,175	4,560	-	-	88,378	88,792
Segment results	25,432	24,749	(94)	1,128	-	-	25,338	25,877
Finance costs	(2,338)	(2,678)	(2)	(22)	-	-	(2,340)	(2,700)
Depreciation of plant and equipment	(2,176)	(1,963)	(26)	(303)	-	-	(2,202)	(2,266)
Depreciation right-of-use assets	(6,256)	(6,111)	(234)	(417)	-	-	(6,490)	(6,528)
Amortisation of intangible assets	(162)	(150)	(148)	(101)	-	-	(310)	(251)
Unallocated – corporate expenses	-	-	-	-	(9,057)	(2,635)	(9,057)	(2,635)
Share of profit from equity-accounted associate	-	-	-	-	(103)	68	(103)	68
Profit before income tax	14,500	13,847	(504)	285	(9,160)	(2,419)	4,836	11,565
Income tax expense	(821)	(1,388)	(11)	(142)	-	-	(832)	(1,530)
Profit, net of tax	13,679	12,459	(515)	143	(9,160)	(2,419)	4,004	10,035
Expenditure for non-current assets								
Property, plant and equipment	(1,591)	(2,111)	(2)	(38)	-	-	(1,593)	(2,149)
Other material non-cash items								
Loss on deemed disposal of associates	-	-	-	-	(4,343)	-	(4,343)	-
Compensation from ex-vendors	-	-	-	-	-	1,437	-	1,437
Allowance on plant and equipment	(6)	-	-	-	-	-	(6)	-
Allowance on inventories	(69)	(32)	-	-	-	-	(69)	(32)
Gain on partial disposal of subsidiary	-	436	-	-	-	-	-	436

¹ Refer to note 17



2C. Assets and reconciliation

	As at	
	30 Jun <u>2025</u> \$'000	31 Dec <u>2024</u> \$'000 (Restated) ¹
<u>Segment assets</u>		
Core dental business	261,255	216,814
Other businesses	11,498	4,751
Unallocated – investment in associates	15	25,835
Total	<u>272,768</u>	<u>247,400</u>

2D. Liabilities and reconciliation

	As at	
	30 Jun <u>2025</u> \$'000	31 Dec <u>2024</u> \$'000
<u>Segment liabilities</u>		
Core dental business	145,348	138,360
Other businesses	835	906
Total	<u>146,183</u>	<u>139,266</u>

2E. Geographical information

The Group operations are primarily in Singapore, Malaysia and China.

	6 months ended 30 Jun	
	<u>2025</u> \$'000	<u>2024</u> \$'000
<u>Revenue</u>		
Singapore	79,954	83,328
Malaysia	5,738	5,464
China	2,686	-
Total	<u>88,378</u>	<u>88,792</u>

	As at	
	30 Jun <u>2025</u> \$'000	31 Dec <u>2024</u> \$'000 (Restated) ¹
<u>Non-current assets</u>		
Singapore	135,323	133,756
Malaysia	4,817	4,799
China	30,607	24,784
Total	<u>170,747</u>	<u>163,339</u>

Revenues are attributed to countries on the basis of the customer's location, irrespective of the origin of the goods and services. The non-current assets are analysed by the geographical area in which the assets are located.

¹Refer to note 17



3. Revenue

	6 months ended 30 Jun	
	<u>2025</u>	<u>2024</u>
	\$'000	\$'000
Core dental services	84,420	82,640
Other services	1,100	4,534
Profit guarantee income	1,303	926
Rental income	222	254
Other income	1,333	438
Total revenue	<u>88,378</u>	<u>88,792</u>

4. (Other losses) and other gains

	6 months ended 30 Jun	
	<u>2025</u>	<u>2024</u>
	\$'000	\$'000
Gain on disposal of subsidiary (Note 9 ^(a))	-	436
Compensation from ex-vendors	-	1,437
Gain on disposal of plant and equipment	198	-
Loss on consolidation of associates to subsidiaries	(4,343)	-
Plant and equipment written off	(160)	(103)
Foreign exchange translation (loss) gain	(24)	25
Impairment allowance on plant and equipment	(6)	-
Impairment allowance on inventories	(69)	(32)
Net	<u>(4,404)</u>	<u>1,763</u>

5. Finance costs

	6 months ended 30 Jun	
	<u>2025</u>	<u>2024</u>
	\$'000	\$'000
Interest on borrowings	1,507	1,848
Interest on lease liabilities	833	852
Total	<u>2,340</u>	<u>2,700</u>



6. Income tax expense

Components of tax expense recognised in profit or loss include:

	6 months ended 30 Jun	
	<u>2025</u>	<u>2024</u>
	\$'000	\$'000
<u>Current tax expense:</u>		
Current tax expense	827	1,530
Under adjustments in respect of prior periods	52	62
Subtotal	<u>879</u>	<u>1,592</u>
<u>Deferred tax (income) expense:</u>		
Deferred tax income	(55)	(17)
Under (over) adjustments in respect of prior periods	8	(45)
Subtotal	<u>(47)</u>	<u>(62)</u>
Total income tax expense	<u>832</u>	<u>1,530</u>

7. Dividends on equity shares

	Group	
	30 Jun <u>2025</u>	30 Jun <u>2024</u>
	\$'000	\$'000
Second interim tax exempt dividend paid of \$0.0053 with respect of FY2023	-	5,016
Second interim tax exempt dividend paid of \$0.007 with respect of FY2024	6,642	-
	<u>6,642</u>	<u>5,016</u>

8. Property, plant and equipment

During the six months ended 30 June 2025, the Group acquired assets amounting to \$1,593,000 (30 June 2024: \$2,149,000) and disposed of assets amounting to \$160,000 (30 June 2024: \$103,000).

9. Investment in associates

	Group As at	
	30 Jun <u>2025</u>	31 Dec <u>2024</u>
	\$'000	\$'000
Movements in carrying value:		(Restated) ¹
Balance at beginning of the year	25,835	24,587
Addition ^(a)	-	1,109
Deemed disposal ^(b)	(25,174)	-
Foreign currency translation adjustment	(543)	5
Share of (loss) profit for the year	(103)	134
	<u>15</u>	<u>25,835</u>

¹Refer to note 17



9. Investment in associates (cont'd)

- (a) The Group disposed of 51% interest in its subsidiary, EM2AI Pte. Ltd. ("EM2AI"), on 5th March 2024, resulting in a decrease in equity interest from 100% to 49%. The Group has assessed that the control over its subsidiary, EM2AI has been lost and therefore deconsolidated EM2AI on 5th March 2024.
- (b) On 11 April 2025, the Company acquired 51% of the entire issued and paid-up share capital of EM2AI. Following the acquisition, the Company's shareholding interest in EM2AI has increased from 49% to 100%. EM2AI is now a wholly-owned subsidiary of the Company.

On 30 April 2025, the Company acquired 87,973,480 shares of Aoxin Q & M from Health Field Enterprises Limited ("HFEL") pursuant to a share security agreement dated 12 October 2016 entered into by HFEL in favour of the Company. This was for the partial settlement of the profit guarantee amount owed by Dr Shao Yongxin ("Dr Shao").

Following the acquisition, the Company and persons acting in concert with the Company has increased its shareholding percentage in Aoxin Q & M from approximately 33.33% to 50.53%. In accordance with the Rule 14.1 of the Singapore Code on Take-overs and Mergers, the Company will make a mandatory unconditional cash offer ("Offer").

On 16 June 2025, the offer has closed and the total number of Aoxin Q & M shares owned, controlled or agreed to be acquired by the Company amount to an aggregate of 269,323,546 Aoxin Q & M shares, representing 52.65% of the total number of Aoxin Q & M shares. Aoxin Q & M is now a subsidiary of the Company.

10. Goodwill

	<u>Total</u> \$'000
As at 31 December 2024	
Cost	61,214
Accumulated amortisation and impairment	(8,857)
Carrying amounts at 31 December 2024	<u>52,357</u>
Cost	
As at 1 January 2025	61,214
Addition	2,394
Consolidation of subsidiary	22,253
As at 30 June 2025	<u>85,861</u>
Accumulated amortisation and impairment	
As at 1 January 2025 and 30 June 2025	<u>(8,857)</u>
Carrying amounts at 30 June 2025	<u>77,004</u>



10. Goodwill (cont'd)

Additional goodwill arise due to the consolidation of EM2AI from an equity-accounted associate to a subsidiary of the Group on 5 March 2025 as well as the acquisition of Citizen Dental Surgery on 28 March 2025.

Goodwill that has an indefinite useful life is tested for impairment annually, or more frequently if events or changes in circumstances indicated that it might be impaired. No impairment indicators were identified as at 30 June 2025 based on the CGU's business performance.

Since the beginning of the reporting year, there were no changes in the circumstances and key assumptions.

11. Other intangible assets

	Development <u>costs</u> \$'000	Customer <u>lists</u> \$'000	<u>Total</u> \$'000
As at 31 December 2024			
Cost	-	3,321	3,321
Accumulated amortisation and impairment	-	(2,894)	(2,894)
Carrying amounts at 31 December 2024	<u>-</u>	<u>427</u>	<u>427</u>
Cost			
As at 1 January 2025	-	3,321	3,321
Acquisition of subsidiary	<u>6,750</u>	<u>-</u>	<u>6,750</u>
As at 30 June 2025	<u>6,750</u>	<u>3,321</u>	<u>10,071</u>
Accumulated amortisation and impairment			
As at 1 January 2025	-	2,894	2,894
Acquisition of subsidiary	<u>2,653</u>	<u>-</u>	<u>2,653</u>
Amortisation	<u>149</u>	<u>161</u>	<u>310</u>
As at 30 June 2025	<u>2,802</u>	<u>3,055</u>	<u>5,857</u>
Carrying amounts at 30 June 2025	<u>3,948</u>	<u>266</u>	<u>4,214</u>



12. Share capital

	Number of shares <u>issued</u> '000	Share capital <u>\$'000</u>
Ordinary shares of no par value:		
Balance at 31 December 2024 and 30 June 2025	<u>965,865</u>	<u>86,758</u>

The ordinary shares of no par value are fully paid, carry one vote each and have no right to fixed income.

	Number of treasury shares <u>shares</u> '000	<u>Cost</u> \$'000
Balance at 1 January 2024	19,422	11,535
Transfer of treasury shares at \$0.25 cents each ^(a)	(520)	(130)
Transfer of treasury shares at \$0.28 cents each ^(b)	(1,963)	(550)
Share buyback ^(c)	<u>2,814</u>	<u>1,061</u>
Balance at 30 June 2025	<u>19,753</u>	<u>11,916</u>

(a) On 24 June 2024, the Company transferred 520,000 ordinary shares from its treasury shares to 3 key dentists of the Group for an aggregate gross cash consideration of \$130,000.

(b) On 4 September 2024, the Company transferred 1,962,880 ordinary shares from its treasury shares to dentists in the Group pursuant to the Q & M Performance Share plan 2018

(c) In 1H25, the Company bought back 2,814,200 shares by way of market acquisition and all shares are held as treasury shares.

The Company has 19,753,727 treasury shares as at 30 June 2025 (30 June 2024: 18,902,407) and there is no subsidiary holdings as at 30 June 2025 (30 June 2024: Nil).

	As at	
	30 Jun <u>2025</u> '000	31 Dec <u>2024</u> '000
Total number of issued shares excluding treasury shares	<u>946,112</u>	<u>948,926</u>

There were no sales, transfer, disposals, cancellation and/or use of treasury shares as at end of current financial year reported on.



13. Other financial liabilities

	Group As at		Company As at	
	30 Jun 2025 \$'000	31 Dec 2024 \$'000	30 Jun 2025 \$'000	31 Dec 2024 \$'000
<u>Non-current:</u>				
Bank loans	72,998	73,209	67,060	67,167
Finance leases	24	30	-	-
Non-current, total	<u>73,022</u>	<u>73,239</u>	<u>67,060</u>	<u>67,167</u>
<u>Current:</u>				
Bank loans	5,489	489	5,246	246
Finance leases	14	15	-	-
Current, total	<u>5,503</u>	<u>504</u>	<u>5,246</u>	<u>246</u>
Total	<u>78,525</u>	<u>73,743</u>	<u>72,306</u>	<u>67,413</u>

13A. Bank loans

	Group As at		Company As at	
	30 Jun 2025 \$'000	31 Dec 2024 \$'000	30 Jun 2025 \$'000	31 Dec 2024 \$'000
Amount repayable within one year	5,489	489	5,246	246
Amount repayable after one year	<u>72,998</u>	<u>73,209</u>	<u>67,060</u>	<u>67,167</u>

Bank loans amounting to \$11.0 million (31 December 2024: \$11.2 million) are secured by legal mortgage of the Group's properties and covered by corporate guarantee from the Company.

13B. Finance leases

	Group As at	
	30 Jun 2025 \$'000	31 Dec 2024 \$'000
Amount repayable within one year	14	15
Amount repayable after one year	<u>24</u>	<u>30</u>

The finance leases are secured on the plant and equipment under finance leases.



14. Categories of financial assets and liabilities

The following table categories the carrying amount of financial assets and liabilities recorded at the end of the reporting period:

	Group As at		Company As at	
	30 Jun	31 Dec	30 Jun	31 Dec
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
	\$'000	\$'000	\$'000	\$'000
<u>Financial assets:</u>				
Financial assets at amortised cost	88,580	73,256	88,369	91,933
At end of the period	<u>88,580</u>	<u>73,256</u>	<u>88,369</u>	<u>91,933</u>
<u>Financial liabilities</u>				
Financial liabilities at amortised cost	141,609	134,001	106,860	98,514
At end of period	<u>141,609</u>	<u>134,001</u>	<u>106,860</u>	<u>98,514</u>

15. Net asset value

	Group As at		Company As at	
	30 Jun	31 Dec	30 Jun	31 Dec
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
		(Restated) ¹		
Net assets value per ordinary share (cents)	<u>10.9</u>	<u>11.1</u>	<u>9.5</u>	<u>9.9</u>

¹ Refer to Note 17

The net asset value per ordinary share of the Group and the Company as at 30 June 2025 has been calculated based on the total issued number of ordinary shares excluding treasury shares of 946,111,620 (2024: 948,925,820).

16. Events after the end of the reporting period

There are no known subsequent events which have led to adjustments to this set of condensed interim financial statements.

17. Restatement of prior period financial statements

During the six months ended 30 June 2025, upon the request of the National Healthcare Security Administration 国家医疗保障局 (“NHSA”), a Chinese government agency that oversees, *inter alia*, the nation’s health insurance plan and centralized purchasing of drugs and medical supplies, Aoxin Q & M conducted a self-review exercise on two of the hospitals, namely Shenyang Aoxin Q & M Stomatology Hospital Co., Ltd. and Shenyang City Shenhe District No. 6 Hospital (Shenyang Aoxin Q & M Stomatology Hospital Co., Ltd. – Branch Hospital) (the “Hospitals”). Further to the self-review, NHSA and the Hospitals concluded that there was an excess claim of cost of material from NHSA amounting in aggregate to approximately RMB6.2 million for FY2024. This overclaim resulted in an overstatement of revenue and understatement of liabilities in the twelve months period ended 31 December 2024. The overstatement of revenue and understatement of liabilities have been adjusted retrospectively by Aoxin Q & M. As a result, the Group’s consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes of equity, consolidated statement of cash flows and earning per share of the Group for 1H2024, 2H2024 and FY2024 had since been restated.



17. Restatement of prior financial statements (cont'd)

The following table summarises the impact of the statement on the affected line items if 1H2024, 2H2024 and FY2024 financial statements:

	<u>Previously reported</u> \$'000	<u>Adjustment</u> \$'000	<u>Restated</u> \$'000
<u>Group</u>			
<u>Consolidated Statement of Profit or Loss and Other Comprehensive Income for the six months ended 30 June 2024</u>			
Share of profit from equity-accounted associates	216	(148)	68
<u>Consolidated Statement of Changes in Equity as at 30 June 2024</u>			
Retained earnings	32,624	(148)	32,476
Attributable to owners of the Company	104,000	(148)	103,852
Total equity	108,224	(148)	108,076
<u>Consolidated Statement of Changes in Cash Flows for the six months ended 30 June 2024</u>			
Profit before tax	11,713	(148)	11,565
Share of profit from equity-accounted associates	(216)	148	(68)
<u>Earnings per share for the six months ended 30 June 2024</u>			
Basic	1.04	(0.02)	1.02
Diluted	1.04	(0.02)	1.02
<u>Consolidated Statement of Profit or Loss and Other Comprehensive Income for the six months ended 31 December 2024</u>			
Share of profit from equity-accounted associates	507	(373)	134
<u>Statements of Financial Position as at 31 December 2025</u>			
Investment in associates	26,208	(373)	25,835
Retained earnings	33,674	(373)	33,301
<u>Net Assets Value per Ordinary Share as at 31 December 2025</u>			
	11.2	(0.1)	11.1



Other Information Required by Listing Rule 7.2

- 1. Whether the figures have been audited or reviewed and in accordance with auditing standards or practice.**

The condensed interim consolidated financial statement and notes for the first half ended 30 June 2025 have not been reviewed / audited by the Company's auditor.

- 2. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business. It must include a discussion of the following:**
 - a) any significant factors that affected the turnover, costs, and earnings of the Group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**
 - b) any material factors that affected the cash flow, working capital, assets or liabilities of the Group during the current financial period reported on.**

Statement of Comprehensive Income

Revenue

In Singapore, the Group has 108 dental outlets, 5 medical outlets, 1 dental college and 1 dental equipment & supplies distribution company as at 30 June 2025 compared to 104 dental outlets, 5 medical outlets, 1 dental college, 1 dental equipment & supplies distribution company and 1 medical laboratory company as at 30 June 2024.

In Malaysia, the Group has 37 dental outlets and 1 dental equipment & supplies distribution company as at 30 June 2025 compared to 44 dental outlets and 1 dental equipment & supplies distribution company as at 30 June 2024.

In China, the Group has 7 dental polyclinics, 7 dental hospital, 5 dental training centres, 2 dental distribution & supplies company and 3 dental laboratories as at 30 June 2025.

The revenue contribution from core dental business increased by 4% from \$84.2 million for the first six months ended 30 June 2024 ("1H24") to \$87.2 million for the first six months ended 30 June 2025 ("1H25"). The increase of \$3.0 million was mainly due to the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25, higher revenue contribution from the Group's equipment & supplies distribution companies in Singapore and Malaysia offset by marginally lower revenue contribution from Singapore dental clinics.

The revenue contribution from the other businesses decreased by 74% from \$4.6 million in 1H24 to \$1.2 million in 1H25. The decrease of \$3.4 million was mainly due to the cessation of the Group's medical laboratory in September 2024 due to the expiry of the clinical laboratory service licence.



Other (Losses) Gains – Net

Net other losses of \$4.4 million in 1H25 was mainly due to the loss arising from the deemed disposal of Aoxin Q & M and EM2AI when the Group gained control of these entities and reclassified them from equity-accounted associates to subsidiaries of the Group in 1H25.

Net other gains of \$1.8 million in 1H24 was mainly due to gain on disposal of EM2AI as well as compensation from ex-vendors for the settlement and termination deed for Shanghai Chuangyi Investment & Management Co., Ltd. and ex-vendors from AR Dental Supplies Sdn. Bhd..

Other Items of Expense

Cost of Sales from Core Dental Business

Cost of sales from core dental business increased by 16% from \$8.4 million in 1H24 to \$9.7 million in 1H25. The increase of \$1.3 million was mainly due to the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25.

As a percentage of revenue from the core dental business, cost of sales used in the core dental business in 1H25 was 11.1% compared to 9.9% in 1H24.

Cost of Sales from Other Businesses

The cost of sales from other businesses decreased by 84% from \$1.3 million in 1H24 to \$0.2 million in 1H25. The decrease of \$1.1 million was mainly due to the cessation of the Group's medical laboratory in September 2024 due to the expiry of the clinical laboratory service licence.

As a percentage of revenue from other businesses, cost of sales used in other businesses in 1H25 was 17.9% compared to 28.2% in 1H24.

Other Expenses

Other expenses increased by 12% from \$5.5 million in 1H24 to \$6.2 million in 1H25. The increase of \$0.7 million was mainly due to the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25, as well as increase in credit card commission charges, insurance expense and legal and professional fees for the Group's Singapore operation.

As a percentage of revenue, other expenses in 1H25 was 7.0% compared to 6.2% in 1H24.



Finance Costs

Finance costs decreased by 13% from \$2.7 million in 1H24 to \$2.3 million in 1H25. The decrease of \$0.4 million was due to lower interest expense in 1H25.

As a percentage of revenue, finance costs in 1H25 was 2.6% compared to 3.0% in 1H24.

Share of (Loss) Profit from Equity-Accounted Associates

The Group recorded a share of loss from equity-accounted associates of \$0.1 million in 1H25 due to a share of loss from equity-accounted associate, EM2AI, offset by a share of profit from equity-accounted associate, Aoxin Q & M. EM2AI and Aoxin Q & M are now subsidiaries of the Group.

The Group recorded a share of profit from equity-accounted associates of \$0.1 million in 1H24 mainly due to a share of profit contributed by the equity-accounted associate, Aoxin Q & M.

Profit Before Tax and Net Profit After Tax

The Group's profit before tax decreased from \$11.6 million in 1H24 to \$4.8 million in 1H25. The Group's net profit after tax decreased from \$10.0 million in 1H24 to \$4.0 million in 1H25.

Excluding the impact of other gains and losses, the Group's net profit after tax without the other gains and losses increased from \$8.3 million in 1H24 to \$8.4 million in 1H25.

Profit attributable to owners of the parent decreased from \$9.7 million in 1H24 to \$3.9 million in 1H25. Excluding the impact of other gains and losses, profit attributable to owners of the parent increased from \$7.9 million in 1H24 to \$8.3 million in 1H25.

Statement of Financial Position

As at 30 June 2025, the Group has cash and cash equivalents of \$47.1 million while bank borrowings plus finance leases amounted to \$78.5 million. As at 31 December 2024, the Group has cash and cash equivalents of \$34.3 million while bank borrowings plus finance leases amounted to \$73.7 million.

Current Assets

Inventory as at 30 June 2025 increased to \$12.4 million from \$10.6 million as at 31 December 2024. The increase of \$1.8 million was mainly due to the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25 offset by decrease in inventory from the dental equipment & supplies distribution company in Malaysia.



Trade and other receivables as at 30 June 2025 increased to \$38.9 million from \$36.0 million as at 31 December 2024. The increase of \$2.9 million was mainly due to the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25 offset by loan due from EM2AI now recognised as a subsidiary receivables following the consolidation of EM2AI from an equity-accounted associate to a subsidiary in 1H25 as well as decrease in profit guarantee receivable.

Other assets as at 30 June 2025 increased to \$3.6 million from \$3.2 million as at 31 December 2024. The increase of \$0.4 was mainly due to increase in prepayment arising from the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25.

Non-Current Assets

The net book value of property, plant and equipment as at 30 June 2025 increased to \$40.9 million from \$37.1 million as at 31 December 2024. The increase of \$3.8 million was mainly due to the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25 offset by depreciation for plant and equipment.

The net book value of ROU asset as at 30 June 2025 increased to \$40.3 million from \$38.2 million as at 31 December 2024. The increase of \$2.1 million was due to the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25 and opening of new clinics offset by depreciation of the ROU assets.

Investment in associates as at 30 June 2025 decreased to \$15k from \$25.8 million as at 31 December 2024. The decrease of \$25.8 million due to the consolidation of Aoxin Q & M and EM2AI from equity-accounted associates to subsidiaries of the Group in 1H25.

Goodwill as at 30 June 2025 increased to \$77.0 million from \$52.4 million as at 31 December 2024. The increase of \$24.6 million was mainly due to the consolidation of Aoxin Q & M and EM2AI from equity-accounted associates to subsidiaries of the Group in 1H25.

Other intangible assets as at 30 June 2025 increased to \$4.2 million from \$0.4 million as at 31 December 2024. The increase of \$3.8 million was mainly due to the consolidation of Aoxin Q & M and EM2AI from equity-accounted associates to subsidiaries of the Group in 1H25 offset by amortisation of other intangible assets in 1H25.

Other receivables as at 30 June 2025 decreased to \$2.6 million from \$2.9 million in 31 December 2024. The decrease of \$0.3 million was due to the repayment of loan by the dentists of the Company.

Other assets as at 30 June 2025 decreased to \$5.8 million from \$6.5 million as at 31 December 2024. The decrease of \$0.7 million was due to amortisation of sign on bonus for dentists.

Current Liabilities

Trade and other payables as at 30 June 2025 increased to \$20.3 million from \$18.6 million as at 31 December 2024. The increase of \$1.7 million was mainly due to the consolidation of Aoxin Q & M and EM2AI from equity-accounted associates to subsidiaries of the Group in 1H25 offset payment of professional fees to dentists, doctors and staff bonuses which were accrued as at 31 December 2024.



Other financial liabilities as at 30 June 2025 increased to \$5.5 million from \$0.5 million as at 31 December 2024. The increase of \$5.0 million was due to draw down of \$5.0 million bank loan.

Non-Current Liabilities

Lease liabilities from ROU assets as at 30 June 2025 increased to \$31.8 million from \$30.7 million as at 31 December 2024. The increase of \$1.1 million was mainly due to the consolidation of Aoxin Q & M from an equity-accounted associate to a subsidiary of the Group in 1H25, renewal of operating leases and opening of new clinics offset by repayment of operating lease.

Statement of Cash Flows

The Group generated net cash flow from operating activities of \$15.0 million in 1H25. This was mainly derived from the profit generated from operations in 1H25 offset by decrease in trade and other payables and income taxes paid.

Net cash from investing activities in 1H25 amounted to \$9.9 million, mainly due to consolidation of Aoxin Q&M and EM2AI from equity-accounted associates to subsidiary of the Group and decrease in sign on bonus for dentists offset by the purchase of plant and equipment for the existing and new dental clinics.

Net cash used in financing activities in 1H25 was \$12.2 million, mainly due to repayment of lease liabilities arising from right-of use assets, dividend payment to shareholders offset by proceeds from term loan.

Consequent to the above factors, the Group's cash and cash equivalents was \$47.1 million as at 30 June 2025.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

No forecast had been issued for the current financial reporting period. The financial results are in line with the expectations as disclosed in previous quarterly announcement.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.

Industry Prospects

Barring any unforeseen circumstances, there are no known significant changes in the trends and competitive conditions of the industry in which the Group operates and no other major known factors or events that may adversely affect the Group in the next reporting period and the next 12 months.



Recent Developments and Future Plans

With the Company's recent successful issuance of \$130 million in 3.95% notes that demonstrated strong investor interest, the Management is actively looking for M&A and organic expansion opportunities to allocate the proceeds in a strategic and value-accretive manner.

The Group remains committed to expanding its network of clinics in Singapore, primarily through organic growth alongside strategic acquisitions that are value-accretive to the business. To support this expansion, talent acquisition and retention will be a key focus, ensuring the Group has the necessary human capital to meet the growing demand.

Beyond Singapore, Q & M is actively exploring opportunities to expand its dental business, particularly in the Johor-Singapore Special Economic Zone with the upcoming Rapid Transit System ('RTS'). The Company is considering various strategies to mitigate the potential outflow of patients to Johor, who may seek to capitalise on the financial advantages of the currency exchange rate once the RTS becomes operational around December 2026.

At the same time, the Company is aware that PRC's dental market is undergoing a rapid consolidation phase. As a result, Q & M is carefully evaluating opportunities to expand its dental business in China.

5. Dividend

(a) Current Financial Period Reported On

Any dividend declared for the current financial period reported on? Yes

Name of dividend	First Interim
Dividend type	Cash
Dividend amount per share (in cents)	0.40 cent per ordinary share
Tax rate	One tier tax exempt

(b) Corresponding Period of the immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year? Yes

Name of dividend	First Interim
Dividend type	Cash
Dividend amount per share (in cents)	0.40 cent per ordinary share
Tax rate	One tier tax exempt

(c) The date the dividend is payable.

First Interim Dividend

The dividend will be paid on 4 September 2025.



(d) Book closure date

First Interim Dividend

Notice is hereby given that Share Transfer Books and Register of Members of the Company will be closed on 22 August 2025 on which day no share transfer will be effected.

Duly completed and stamped transfers received by the Company's Share Registrar, Tricor Barbinder Share Registration Services (a division of Tricor Singapore Pte. Ltd.), 9 Raffles Place, #26-01 Republic Plaza, Singapore 048619, up to 5.00 p.m. on 21 August 2025 will be registered to determine members' entitlements to the interim dividend. Members (being depositors) whose securities account with The Central Depository (Pte) Limited are credited with ordinary shares in the capital of the Company as at 5.00 p.m. on 21 August 2025 will be entitled to the payment of the interim dividend.

6. If no dividend has been declared (recommended), a statement to the effect.

Not applicable.

7. If the Group has obtained a general mandate from shareholders for Interested Parties Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to the effect.

The Group did not obtain a general mandate from shareholders for IPTs.

8. Confirmation pursuant to Rule 720 (1) of the Listing Manual

The Company hereby confirms that it has procured undertakings from all its directors and executive officers under Rule 720 (1) of the Listing Manual.

9. Confirmation by the Board pursuant to Rule 705 (5) of the Listing Manual

On behalf of the Board of Directors of the Company, we, the undersigned directors, do hereby confirm that, to the best of our knowledge, nothing has come to the attention of the Board of Directors of the Company that may render the condensed interim financial statements to be false or misleading in any material aspect.

On behalf of the Board of Directors

Dr Ng Chin Siau
Group CEO & Executive Director

Mr Lim Yeow Hua
Independent Non-Executive Director

14 August 2025